Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator The_Free_Nebula, BuyMyAsk, dr_lowenstein, eColi
Search This Board:
Last Post: 7/7/2015 11:09:35 PM - Followers: 179 - Board type: Free - Posts Today: 0
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for CTSO
CTSO News: Statement of Changes in Beneficial Ownership (4) 07/07/2015 10:44:32 AM
CTSO News: Statement of Changes in Beneficial Ownership (4) 06/26/2015 02:38:29 PM
CTSO News: Statement of Changes in Beneficial Ownership (4) 06/22/2015 04:20:51 PM
CTSO News: CytoSorbents Corporation set to join Russell Microcap Index 06/19/2015 07:00:00 AM
CTSO News: Statement of Changes in Beneficial Ownership (4) 06/15/2015 02:22:31 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 07/07/2015 10:44:32 AM
#7161  Sticky Note Recap of 2015 so far andy55q 05/19/15 07:46:11 AM
#6174  Sticky Note From Yahoo MB-Updated Cytosorbents Overview andy55q 12/19/14 10:40:16 AM
#7226   Irish government attacks sepsis with new national effort andy55q 07/07/15 11:09:35 PM
#7225   Hospital readmissions for sepsis are highly common, extremely costly andy55q 07/07/15 10:40:47 PM
#7224   America's Costliest Health Condition: Sepsis, A Relatively Little-Known andy55q 07/07/15 10:33:27 PM
#7223   Prof Brunkhorst, general secretary of the German Sepsis andy55q 07/06/15 08:13:14 AM
#7222   Import Data and Price of CytoSorb. Based on ping_pow_princess 07/04/15 02:03:00 AM
#7221   Sepsis Is Largely Unknown But It Puts One andy55q 07/01/15 10:29:56 PM
#7220   Numbers update from EXIM andy55q 07/01/15 11:33:54 AM
#7219   Some Might Find This Article From 2011 Very Interesting andy55q 06/28/15 04:42:17 PM
#7218   Sepsis Conference Sept 9-11, Weimar ping_pow_princess 06/27/15 11:43:56 PM
#7217   Did people make money here? I don't BuyMyAsk 06/25/15 04:24:24 PM
#7216   nice to see green here The_Free_Nebula 06/24/15 05:27:30 PM
#7215   And another great day. Last week's buys were rule_rationale 06/23/15 04:06:22 PM
#7214   What happen to BuyMyAsk ? andy55q 06/22/15 09:03:19 AM
#7213   2nd International CytoSorb Users’ Meeting andy55q 06/21/15 01:15:54 PM
#7212   I would not jump to the conclusion that orangecat 06/19/15 11:13:56 AM
#7211   2 more urgent purchases on cytosorb in Italy andy55q 06/19/15 07:59:49 AM
#7210   NEWS -- CytoSorbents Corporation set to join Russell Paulness 06/19/15 07:51:53 AM
#7209   Paulness, Good remark on XON. See, once CTSO gets caesare74 06/18/15 05:33:31 PM
#7208   Future growth needs a fundament. And exactly this SABAI 06/18/15 04:23:38 PM
#7207   Look at horrible earnings look at XON and Paulness 06/18/15 04:04:27 PM
#7206   I predict next earnings to be horrible. Clinical SABAI 06/18/15 03:00:07 PM
#7205   Lest you all forget andy55q 06/17/15 07:05:37 PM
#7204   Its quiet around the "SUPERSTAR". Did some of SABAI 06/17/15 06:04:51 PM
#7203   ping_pow-princess Good to hear from you...From Yahoo MB andy55q 06/16/15 02:06:06 PM
#7202   If they dont show clinical benefit soon there SABAI 06/16/15 01:12:10 PM
#7201   Sepsis: A Neglected Global Killer andy55q 06/15/15 04:34:54 PM
#7200   CTSO is a long term investment for me. vinovista 06/15/15 12:17:29 PM
#7199   The DJIA is down triple digits. Problems with mh1156 06/15/15 11:54:16 AM
#7198   Wow down .30 with the addition to Russel. vinovista 06/15/15 11:23:30 AM
#7197   CTSO has been added to the Russell microcap.> mh1156 06/13/15 10:12:20 AM
#7196   New base formed.... The_Free_Nebula 06/11/15 09:13:40 AM
#7195   Italian Hospital buys 6 Cytosorb Catridges andy55q 06/11/15 07:07:35 AM
#7194   Little known disease with no efficacy proved filter SABAI 06/10/15 12:46:22 PM
#7193   Little Known Disease Accounts for 4 in 10 andy55q 06/09/15 07:43:37 AM
#7192   New Study-Septic Shock andy55q 06/06/15 08:07:44 AM
#7191 Visit our Symposium! andy55q 06/05/15 09:10:17 AM
#7190   Kidney failure impacts survival of sepsis patients andy55q 06/05/15 08:23:21 AM
#7189   WEBINAR: 04 June about ?#?sepsis? with Prof. Konrad andy55q 06/03/15 09:39:24 AM
#7188   andy55q- Thank you for all your efforts to bkmomail 06/03/15 09:18:51 AM
#7187   New Video updates 2015- Good info andy55q 06/02/15 09:49:20 PM
#7186   No. Not at this time. andy55q 05/30/15 06:58:55 AM
#7185   Andy, do you have an idea about the results caesare74 05/29/15 12:42:42 PM
#7184   Thank You Andy. Very good info. Looks rdgere 05/28/15 09:05:07 AM
#7183   Cytosorb Registry-PARTICIPATING CLINICAL CENTERS andy55q 05/28/15 08:54:40 AM
#7182   Herpes viruses can cause blood poisoning andy55q 05/28/15 08:40:57 AM
#7181   Important CytoSorb experience exchanges took place in Brussels andy55q 05/27/15 10:53:17 PM
#7180   Case report: CytoSorb treament in 4 patients. Prachee andy55q 05/27/15 10:46:35 PM
#7179   Case report:. Cytosorb a novel treatment option in andy55q 05/27/15 10:29:32 PM
#7178   Confidential Treatment Order - very interesting! eom rule_rationale 05/27/15 05:27:12 PM
#7177   I would be the first to admit this Karlandang 05/26/15 09:35:02 PM